

Biodeal Pharmaceuticals

Be Healthy Together



DSIR APPROVED R&D Facility

Established Manufacturer

- Leading Manufacturer in India Since 2005 with integrated facilities
- Manufacturing more than 1000 brands of 30 categories.
- Total Land Area: 20910 Sq. meter
- Total Build up Area: 9042 Sq. meter

Global Reach

- More than 30+ Countries
- Major: Chile, Ukraine, Kenya, Ghana, Uzbekistan, Cambodia, Myanmar etc.

Domestic Products : Approx. 1000 brands, with 30 categories

Regulatory Excellence & Quality Standards

- WHO-GMP
- Indian GMP & GLP
- PIC,s
- Cambodia GMP
- Uzbekistan
- Tanzania TMDA
- ISO 9001:2015
- Rigorous quality control process in Inventory Management, QC,QA & Production Department.
- We follow Higher management internal audits system.

Our R&D Facility

Location: Integrated with our Production Plant situated at Himachal Pradesh

Facility is approved by DSIR.

Total team of 30 research scientists highly qualified (PhD, M. Pharmacy, M.Sc.)

We are developing Pharmaceuticals, Herbal & Nutraceuticals as well Cosmetics.



Our R&D Facility

Dosage Forms

- Specialized in Nasal Sprays & DPI, equipped with in house testing facilities for Spray Pattern, Plume Geometry (ADSA, Innova systems) & Droplet size Distribution (Sympatec) etc.

Other Products

- Tablets, Capsules,
- Ointments, Creams,
- Gels, Cosmetics, Dusting powders


Equipment List

- HPLCs (Shimadzu & Waters)- 10 Nos.
- Dissolution Apparatus: 2 Nos.
- Rapid mixer Granulator, Blender
- Mini Multi Mill Model GMP
- 16 STN SRTM GMP Model Combo Tooling compression Machine
- Photo-stability Chamber
- Osmolality tester
- Hot Air Oven
- Stability Chambers: ACC and Long Term
- Analytical Balance
- Overhead stirrer, magnetic stirrer, homogenizer, centrifuges like lab instruments

R&D Facility-Innova Systems, Inc. Nasal Sprays Testing Instrument



NSP UA - Actuation Station



ISI-5000 Aerosol Drug Spray Analyzer



R&D Facility-Sympatec. system for droplet size distribution-r-61000- helios

DCGI-Product list

DCGI-First Time Approvals in India

- Midazolam 1.25% w/v- Nasal Spray
- Glycopyrronium 25 mcg, Formoterol Fumarate 12 mcg & Budesonide 400 mcg – DPI
- Vilanterol 25 mcg + Fluticasone 500 mcg – DPI
- Mometasone + Azelastine Nasal Spray

DCGI PRODUCTS UNDER PIPELINE

20 products are in PIPELINE for DCGI approval in various stage.

International Projects – In Licensing

- TWO Nasal Spray PRODUCTS are under process for Clinical Trial in INDIA / US / UK and subsequently Launch Global market. Both product are First Time in Global Category.
- One Sachet Product from EU is in progress for DCGI approval and India Launch

Products Developed and Commercialized

Products	Year Of Launch
Levocetirizine Hydrochloride Tablets IP	2024
Ramipril & Hydrochlorothiazide Tablets IP	2024
Fluticasone Furoate & Oxymetazoline Nasal Spray	2024
Torsemide Tablets IP 100 mg	2024
Fluticasone Furoate 200 Mcg and Vilanterol 25 mcg Powder for Inhalation	2024
Nicotine Nasal Spray BP	2023
Paracetamol Bilayered Sustained Release Tablets	2024

Products	Year Of Launch
Permethrin Cream 5% w/w	2024
Thyroxine Tablets IP 37.5 mcg	2024
Lamotrigine Dispersible Tablets IP 25 mg	2024
Adapalene gel 0.1% w/w	2024
Sildenafil Tablets IP 100 mg	2024
Terbinafine Dusting Powder 1% w/w	2024
Bilastine 20 mg and Montelukast 5/10 mg Tablets	2024

Product Developed & Exported

Products	Year	Country
Bilastine 20 mg and Montelukast 5 mg Tablets	2024	Tajikistan
Budesonide aqueous nasal spray BP 200mcg	2024	Lebanon
Lyophilized Saccharomyces Boulardii Sachets	2024	Myanmar
Mefenamic acid and Drotaverine Hydrochloride Tablets	2023	Moldova
Gliclazide tablets BP 60mg	2023	Moldova
Sofosbuvir & Velpatasvir Tablets	2023	Turkmenistan
Boric Acid Powder 10gm	2023	Moldova
Paracetamol & Phenylephrine HCL Sachet	2023	Ukraine
Calovera Therapy Lotion	2023	Mayanmar
Oat Meal Lotion	2023	Mayanmar
Modified Lanolin	2024	Mayanmar
Esomeprazole Magnesium Delayed - Release Capsules USP 40 mg	2024	Afghanistan
Budesonide Aqueous Nasal Spray BP 200mcg	2024	Lebanon
Ciclopirox Nail Lacquer 8.0 % w/v	2024	Ukraine
Desmopressin Intranasal Solution BP	2023	Turkmenistan

Generic Products Under Development

- Product in line with Gaviscon double action Anatacid oral Suspension (Raft Formulation)
- Sitagliptin and Sitagliptin+Metformin tablets (50mg, 100mg, 50+500mg & 50+1000mg)
- Melatonin Capsules BP 3mg
- Empagliflozin 10mg and 25mg Tablets
- Empagliflozin+ Metformin IR Tablets (12.5/500 mg; 12.5/1000 mg and 5/500 mg)
- Dapagliflozin + Metformin Tablets (10/1000mg; 10/500 mg and 5/500 mg)
- Mometasone + hydroquinone Tretinoin Cream
- Saline water + Hyaluronic acid (0.9%+0.2%) Nasal spray
- Saline water + Eucalyptus Nasal Spray
- Saline water + Carageenan Nasal Spray
- Preservative Free Nasal Spray Technology Development
- Sodium Hyaluronate Eye drop and other tear drops
- Many Ayush and Nutraceutical Formulations
- Sunscreen Lotions and lip Balm Formulations

Why to Collaborate with Biodeal ?

Single Point Solution: We provides single point solution from initial R&D Development to Commercialization of Product.

We provide all below mentioned Services:

- ✓ Regulatory Support (CT-10, FORM-29, Product Permissions, Dossier Preparation, Regulatory Filing Domestic & Export. Loan License etc.)
- ✓ Formulation Development Support (Compatibility studies, Comparative dissolution studies, PDR to PV Batches scale up to Production facilities)
- ✓ Analytical Supports: Method Dev & Analytical Method Validation/Verification
- ✓ Manufacturing Supports: Pilot batch/ Registration batch supports/ Clinical Trial batch Mfg., Packaging supports

Partnering Opportunities & Tailored Services

Flexible Model:

- Contact R&D Development
- Co-Development
- Technology Transfer

Custom Development:

- Formulation Design
- Analytical Method Development
- Scale up support

Why Collaborations is Important?

- ✓ Accelerated Drug Development: Strengths Addition
- ✓ Access to Formulation and Analytical Expertise and Technology
- ✓ Reduced Costs of manufacturing: Resources & Expertise sharing
- ✓ Increased Innovation: Bring together diverse perspectives & Ideas
- ✓ Early Market Access: Open new markets based on Customer requirements

Thank You